MA39885A - Procédés de caractérisation et de traitement de la leucémie myéloïde aiguë - Google Patents

Procédés de caractérisation et de traitement de la leucémie myéloïde aiguë

Info

Publication number
MA39885A
MA39885A MA039885A MA39885A MA39885A MA 39885 A MA39885 A MA 39885A MA 039885 A MA039885 A MA 039885A MA 39885 A MA39885 A MA 39885A MA 39885 A MA39885 A MA 39885A
Authority
MA
Morocco
Prior art keywords
myeloid leukemia
acute myeloid
treating acute
characterizing
methods
Prior art date
Application number
MA039885A
Other languages
English (en)
Inventor
Yelena Kovtun
Robert J Lutz
Paul Noordhuis
Gerrit Jan Schuurhuis
Russell Marlin Walker
Kathleen R Whiteman
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MA39885A publication Critical patent/MA39885A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés permettant de caractériser et de traiter la leucémie myéloïde aiguë (lma) (par exemple, une lma nouvellement diagnostiquée, en récidive et réfractaire) chez un sujet au moyen des immunoconjugués de l'invention.
MA039885A 2014-05-20 2015-05-19 Procédés de caractérisation et de traitement de la leucémie myéloïde aiguë MA39885A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462001015P 2014-05-20 2014-05-20
US201462011456P 2014-06-12 2014-06-12
US201462075715P 2014-11-05 2014-11-05

Publications (1)

Publication Number Publication Date
MA39885A true MA39885A (fr) 2015-11-26

Family

ID=54554957

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039885A MA39885A (fr) 2014-05-20 2015-05-19 Procédés de caractérisation et de traitement de la leucémie myéloïde aiguë

Country Status (13)

Country Link
US (1) US20170080102A1 (fr)
EP (1) EP3145542A4 (fr)
JP (1) JP2017517507A (fr)
KR (1) KR20170004003A (fr)
CN (1) CN106456762A (fr)
AU (1) AU2015264322A1 (fr)
BR (1) BR112016026730A2 (fr)
CA (1) CA2947602A1 (fr)
IL (1) IL248555A0 (fr)
MA (1) MA39885A (fr)
RU (1) RU2016147398A (fr)
SG (1) SG11201609357PA (fr)
WO (1) WO2015179400A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1578446E (pt) * 2002-11-07 2015-07-22 Immunogen Inc Anticorpos anti-cd33 e processo para tratamento de leucemia mieloide aguda usando os mesmos
EP3313884B9 (fr) 2015-06-29 2021-05-19 ImmunoGen, Inc. Anticorps anti-cd 123 et conjugués et dérivés correspondants
EP3469001A4 (fr) * 2016-06-09 2020-05-06 Seattle Genetics, Inc. Combinaisons de conjugués anticorps-médicament à base de pbd avec des d'inhibiteurs de flt3
CA3041843A1 (fr) * 2016-11-02 2018-05-11 Immunogen, Inc. Traitement combine avec des conjugues anticorps-medicament et des inhibiteurs de parp
WO2018183494A1 (fr) * 2017-03-31 2018-10-04 Immunogen, Inc. Conjugués anticorps-médicament ciblant cd19
EP3624839A4 (fr) * 2017-05-17 2021-06-16 Immunogen, Inc. Schémas posologiques d'immunoconjugués anti-cd33
TW201922294A (zh) * 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
TW202003048A (zh) * 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
US20210285933A1 (en) * 2018-07-06 2021-09-16 University Of Washington High throughput drug screening of cancer stem cells
WO2020051013A2 (fr) * 2018-08-24 2020-03-12 The Trustees Of Columbia University In The City Of New York Chimères de ligands anti-cd33 et nkg2d pour le traitement de malignités myéloïdes
JP2022538117A (ja) * 2019-06-26 2022-08-31 メモリアル スローン ケタリング キャンサー センター がんを処置するための抗ｃｄ３３抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007814A (en) * 1992-06-15 1999-12-28 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof
PT1578446E (pt) * 2002-11-07 2015-07-22 Immunogen Inc Anticorpos anti-cd33 e processo para tratamento de leucemia mieloide aguda usando os mesmos
WO2010126552A1 (fr) * 2009-04-30 2010-11-04 Immunogen, Inc. Conjugués de médicament d'agent de liaison cellulaire puissant
US20140148351A1 (en) * 2010-09-30 2014-05-29 The Board Of Trustees Of The Leland Stanford Junior University Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature
CN107335061B (zh) * 2011-02-15 2021-09-07 伊缪诺金公司 细胞毒性苯并二氮杂䓬衍生物
US20120282282A1 (en) * 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates

Also Published As

Publication number Publication date
BR112016026730A2 (pt) 2017-12-12
EP3145542A2 (fr) 2017-03-29
RU2016147398A (ru) 2018-06-21
KR20170004003A (ko) 2017-01-10
RU2016147398A3 (fr) 2019-05-28
IL248555A0 (en) 2016-12-29
WO2015179400A2 (fr) 2015-11-26
CN106456762A (zh) 2017-02-22
CA2947602A1 (fr) 2015-11-26
US20170080102A1 (en) 2017-03-23
SG11201609357PA (en) 2016-12-29
JP2017517507A (ja) 2017-06-29
WO2015179400A3 (fr) 2016-02-04
EP3145542A4 (fr) 2018-01-17
AU2015264322A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
MA39885A (fr) Procédés de caractérisation et de traitement de la leucémie myéloïde aiguë
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12016501411B1 (en) Bifunctional cytotoxic agents
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PH12016501120B1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PE20151672A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
EP4249515A3 (fr) Anticorps anti-cd3 humanisés ou chimériques
EP3806871A4 (fr) Récepteurs antigéniques chimériques bispécifiques à chaîne unique pour le traitement du cancer
MX360707B (es) Receptor antigénico quimérico.
MX2017011432A (es) Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados.
MX2016013999A (es) Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
MX2017003472A (es) Inmunoconjugados que comprenden anticuerpos anti-her2.
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2015015091A (es) Terapia de combinacion de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-farmaco.
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
WO2018119196A8 (fr) Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation